We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marsh & McLennan's (MMC) Q4 Earnings Top Estimates, Rise Y/Y
Read MoreHide Full Article
Marsh & McLennan Companies, Inc. (MMC - Free Report) delivered fourth-quarter 2019 adjusted earnings per share of $1.19, surpassing the Zacks Consensus Estimate by 0.8% on the back of solid revenues. Moreover, the same increased 9.2% year over year.
Marsh & McLennan’s consolidated revenues of $4.3 billion were up 3% on an underlying basis. This upside is majorly attributable to the Risk and Insurances Services plus Consulting Segments. However, the top line missed the Zacks Consensus Estimate by 1.8%.
Total operating expenses of $3.7 billion in the fourth quarter were up 18.8% year over year due to higher compensation and benefits as well as other operating expenses.
Marsh & McLennan Companies, Inc. Price, Consensus and EPS Surprise
Revenues at the Risk and Insurance Services segment were $2.4 billion, up 3% on an underlying basis. Adjusted operating income surged 31% to $550 million from the prior-year quarter’s level.
Marsh, a unit within this segment generated revenues of $2.2 billion, up 3% on an underlying basis. In U.S./Canada, underlying revenues rose 4%.
Underlying revenue growth from international operations of 1% includes 7% increase of the metric in the Asia Pacific and a 2% rise in Latin America. However, the same was partially offset by a 1% dip in EMEA.
Another unit under this segment, Guy Carpenter, displayed 10% revenue growth on an underlying basis in the quarter under review.
Consulting
The Consulting segment's revenues inched up 2% on an underlying basis to $1.9 billion. Also, adjusted operating income was flat at $359 million.
A unit within this segment, Mercer, generated revenues of $1.3 billion, up 4% on an underlying basis. Wealth’s revenues were up 2% on an underlying basis. Health and Career’s revenues were each up 6% and 4% year over year on an underlying basis.
Another unit Oliver Wyman Group registered revenues of $559 million, down 2% on an underlying basis.
Share Repurchase Update
The company bought back shares worth $185 million in the quarter under review.
Financial Update
Marsh & McLennan exited the fourth quarter of 2019 with cash and cash equivalents of nearly $1.2 billion, up 8.3% from the figure at 2018 end.
Cash flow from operations for 2019 totaled $2.3 billion, sliding 2.8% year over year.
As of Dec 31, 2019, Marsh & McLennan’s total assets were $31.3 billion, up 45.1% from the figure as of Dec 31, 2018.
Total equity was $7.9 billion, up 4.7% from the level at 2018 end.
Full-Year Update
For 2019, the company’s revenues of $16.7 billion were up 4% year over year on an underlying basis. Adjusted earnings per share rose 7% year over year to $4.66.
Among other players from the insurance industry having reported fourth-quarter earnings so far, the bottom-line results of Brown & Brown, Inc. (BRO - Free Report) and RLI Corp. (RLI - Free Report) beat estimates while that of Principal Financial (PFG - Free Report) matched the Zacks Consensus Estimate.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Marsh & McLennan's (MMC) Q4 Earnings Top Estimates, Rise Y/Y
Marsh & McLennan Companies, Inc. (MMC - Free Report) delivered fourth-quarter 2019 adjusted earnings per share of $1.19, surpassing the Zacks Consensus Estimate by 0.8% on the back of solid revenues. Moreover, the same increased 9.2% year over year.
Marsh & McLennan’s consolidated revenues of $4.3 billion were up 3% on an underlying basis. This upside is majorly attributable to the Risk and Insurances Services plus Consulting Segments. However, the top line missed the Zacks Consensus Estimate by 1.8%.
Total operating expenses of $3.7 billion in the fourth quarter were up 18.8% year over year due to higher compensation and benefits as well as other operating expenses.
Marsh & McLennan Companies, Inc. Price, Consensus and EPS Surprise
Marsh & McLennan Companies, Inc. price-consensus-eps-surprise-chart | Marsh & McLennan Companies, Inc. Quote
Quarterly Segmental Results
Risk and Insurance Services
Revenues at the Risk and Insurance Services segment were $2.4 billion, up 3% on an underlying basis. Adjusted operating income surged 31% to $550 million from the prior-year quarter’s level.
Marsh, a unit within this segment generated revenues of $2.2 billion, up 3% on an underlying basis. In U.S./Canada, underlying revenues rose 4%.
Underlying revenue growth from international operations of 1% includes 7% increase of the metric in the Asia Pacific and a 2% rise in Latin America. However, the same was partially offset by a 1% dip in EMEA.
Another unit under this segment, Guy Carpenter, displayed 10% revenue growth on an underlying basis in the quarter under review.
Consulting
The Consulting segment's revenues inched up 2% on an underlying basis to $1.9 billion. Also, adjusted operating income was flat at $359 million.
A unit within this segment, Mercer, generated revenues of $1.3 billion, up 4% on an underlying basis. Wealth’s revenues were up 2% on an underlying basis. Health and Career’s revenues were each up 6% and 4% year over year on an underlying basis.
Another unit Oliver Wyman Group registered revenues of $559 million, down 2% on an underlying basis.
Share Repurchase Update
The company bought back shares worth $185 million in the quarter under review.
Financial Update
Marsh & McLennan exited the fourth quarter of 2019 with cash and cash equivalents of nearly $1.2 billion, up 8.3% from the figure at 2018 end.
Cash flow from operations for 2019 totaled $2.3 billion, sliding 2.8% year over year.
As of Dec 31, 2019, Marsh & McLennan’s total assets were $31.3 billion, up 45.1% from the figure as of Dec 31, 2018.
Total equity was $7.9 billion, up 4.7% from the level at 2018 end.
Full-Year Update
For 2019, the company’s revenues of $16.7 billion were up 4% year over year on an underlying basis. Adjusted earnings per share rose 7% year over year to $4.66.
Zacks Rank
Marsh & McLennan carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Insurers
Among other players from the insurance industry having reported fourth-quarter earnings so far, the bottom-line results of Brown & Brown, Inc. (BRO - Free Report) and RLI Corp. (RLI - Free Report) beat estimates while that of Principal Financial (PFG - Free Report) matched the Zacks Consensus Estimate.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>